Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial.
Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P. Delforge M, et al. Among authors: ailawadhi s. Lancet Haematol. 2024 Mar;11(3):e216-e227. doi: 10.1016/S2352-3026(24)00005-X. Lancet Haematol. 2024. PMID: 38423700 Clinical Trial.
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Brown JR, et al. Among authors: ailawadhi s. Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14. Lancet Haematol. 2018. PMID: 29550382 Free PMC article. Clinical Trial.
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Leleu X, et al. Among authors: ailawadhi s. Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):9-22. doi: 10.1016/j.clml.2018.08.016. Epub 2018 Sep 5. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30287200 Review.
Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.
Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, Peters ES, Pawlish K, Bock C, Van Den Berg DJ, Rand KA, Stram D, Conti DV, Auclair D, Colditz GA, Mehta J, Haiman CA, Terebelo H, Janakiraman N, Singhal S, Chiu B, Vij R, Bernal-Mizrachi L, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Cozen W, Ailawadhi S. Yu Y, et al. Among authors: ailawadhi s. JCO Oncol Pract. 2020 Oct;16(10):e1169-e1180. doi: 10.1200/JOP.19.00639. Epub 2020 May 29. JCO Oncol Pract. 2020. PMID: 32469686 Free PMC article.
Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect® MM Registry.
Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Omel JL, Lee HC, Srinivasan S, Kitali A, Agarwal A, Wagner L; CONNECT MM Registry Investigators. Abonour R, et al. Among authors: ailawadhi s. Br J Haematol. 2021 Apr;193(1):93-100. doi: 10.1111/bjh.17131. Epub 2020 Oct 29. Br J Haematol. 2021. PMID: 33118614 Free PMC article.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Among authors: ailawadhi s. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR, Ailawadhi S, Siegel DS, Heffner LT, Somlo G, Jagannath S, Zimmerman TM, Munshi NC, Madan S, Chanan-Khan A, Lonial S, Chandwani S, Minasyan A, Ruehle M, Barmaki-Rad F, Abdolzade-Bavil A, Rharbaoui F, Herrmann-Keiner E, Haeder T, Wartenberg-Demand A, Anderson KC. Kelly KR, et al. Among authors: ailawadhi s. Lancet Haematol. 2021 Nov;8(11):e794-e807. doi: 10.1016/S2352-3026(21)00208-8. Epub 2021 Sep 13. Lancet Haematol. 2021. PMID: 34529955 Clinical Trial.
201 results